A reflection on our 2022 accomplishments, and what’s to come in 2023

As we enter the holiday season, we want to take the opportunity to reflect on a year of significant progress here at Small Pharma. Our CEO, George, wraps up the year in the short video above.

We also want to say a big thank you to everyone who has supported us on our journey – mental health advocates, partners, shareholders, advisors and friends. Thank you for sharing our belief that everyone deserves the option of better mental health, and for supporting us on our mission to develop new treatments for as many patients as possible. 

There are millions of people across the globe who put up with their mental health struggles, because existing treatments do not work for them. We believe this isn’t good enough, and as a team we’ve worked exceptionally hard this year to progress our pipeline exploring short-acting psychedelics with supportive therapy for the treatment of mental health conditions. 

Our goal is to develop treatments that are:

• Fast-acting and long-lasting in their symptom relief
• Scalable to address the critical unmet need
• Accessible to patients, as a reimbursable prescription medicine administered by licensed practitioners, in a clinic setting

As we announced yesterday, the last patient visit has been completed in our Phase IIa proof-of-concept trial for SPL026 in Major Depressive Disorder. We have now moved into data analysis, with results expected early in Q1. This is the first completed placebo-controlled patient study to date exploring a short-acting psychedelic as a potential treatment for Major Depressive Disorder.

2023 is just around the corner. We look forward to sharing the SPL026 Phase IIa results very soon, as well as making progress throughout the year with additional SPL026 trials, and the first-in-human trial with SPL028, our novel deuterated DMT candidate. In line with this significant progress across our portfolio, we look forward to continuing to expand internationally and growing our team as we prepare for a multi-site Phase IIb trial.

Wishing you a wonderful holiday season, and a very happy new year!

The Small Pharma team